Bright Minds Biosciences Inc. (CSE:DRUG)

Bright Minds Biosciences Ratios and Metrics

Market cap in millions CAD. Fiscal year is October - September.

Total Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Nov 5, 2026	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021
Market Capitalization	256	598	7	8	28	107
Market Cap Growth	-54.76%	9016.50%	-19.09%	-71.17%	-73.71%	-
Enterprise Value	-51	547	0	0	19	85
Last Close Price	26.00	84.39	1.47	2.15	8.50	45.20

Price Ratios

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Nov 5, 2026	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021
PB Ratio	0.83	7.29	1.19	1.23	2.67	5.51
P/TBV Ratio	0.83	7.29	1.19	1.23	2.67	5.52

Financial Efficiency

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Nov 5, 2026	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021
Debt / Equity Ratio	0	0.00	0.02	0.01	0.01	-
Net Debt / Equity Ratio	-1.00	-1.01	-1.01	-1.01	-1.09	-1.02
Quick Ratio	121.44	35.68	10.92	24.16	8.00	31.12
Current Ratio	121.97	36.10	11.32	24.26	8.11	31.38
Return on Equity (ROE)	-13.63%	-27.93%	-46.18%	-86.02%	-99.95%	-85.94%
Return on Assets (ROA)	-13.50%	-18.80%	-25.28%	-47.45%	-57.32%	-51.52%
Return on Capital Employed (ROCE)	-12.70%	-16.60%	-47.10%	-109.10%	-138.80%	-44.40%

Yields

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Nov 5, 2026	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021
Earnings Yield	-10.99%	-2.04%	-42.70%	-90.90%	-53.20%	-8.09%
Buyback Yield / Dilution	-38.94%	-59.58%	-15.87%	-50.58%	-37.64%	-148.42%

Data Source: S&P Global Market Intelligence Last updated: Aug 14, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 5, 2026

Data Sources Report a data error